Achema middle east

Yuvraj

Novartis announced Major study published in NEJM confirms Ultibro Breezhaler superiority over Sere

FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients...

GSKs Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule in safety and immunogenicity study in infants and children

GSK presented new data for its meningococcal group B vaccine, Bexsero®,1   comparing safety and immunogenicity with different dosing schedules in infants and young...

Pfizer Announces Results From Two Phase 3 TRUMENBA Studies At The European Society For Paediatric Infectious Diseases Meeting

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains...

Immunosup pressant CellCept Obtained Approval for Additional Indication of “Lupus Nephritis”

Chugai Pharmaceutical Co Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 13,...

Chugai Pharmaceutical Co Ltd. to Take Part in “Relay for Life Japan” Using “3D Adventure Experience (Lung Cancer)” to promote awareness of the early...

Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of “Relay for Life Japan” (Organizer: Japan Cancer Society etc.), a charity activity aiming to support...

EU approves Alprolix (rFIXFc) for the Treatment of Haemophilia B

First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB...

Pfizer reports Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

Translate »